Nature Reviews Nephrology - Table of Contents alert Volume 10 Issue 5

TABLE OF CONTENTS
May 2014 Volume 10 Number 5
Impact Factor 7.943 *	In this issue Research Highlights News and Views Correction Reviews Perspectives Also this month  Featured article: Drug discovery in renal disease—towards a more efficient framework Toshio Miyata, Tsuyoshi Ando, Hisami Hiragi, Kanako Watanabe, Fumi Yamamoto, Douglas E. Vaughan, Tatsuo Kurokawa, Yoshiteru Oshima, Charles van Ypersele de Strihou & Masahiro Takeuchi
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BRAND NEW: Discounts on lab equipment Exclusive prices and information - all in one place! Check our listings before you buy.  VISIT MARKETPLACE TODAY
RESEARCH HIGHLIGHTS Top Cardiovascular disease: Warfarin might be beneficial in nondialysis-dependent patients with CKD and atrial fibrillation Published online: 18 March 2014 p239 | doi:10.1038/nrneph.2014.45 PDF Diabetic nephropathy: Renoprotective effects of angiotensin 1-7 Published online: 11 March 2014 p240 | doi:10.1038/nrneph.2014.39 PDF Acute kidney injury: Hydration status linked to risk of contrast-induced AKI Published online: 04 March 2014 p241 | doi:10.1038/nrneph.2014.33 PDF Glomerular disease: Saving the podocyte—Notch 2 to the rescue Published online: 04 March 2014 p241 | doi:10.1038/nrneph.2014.34 PDF Stones: CSF-1 suppresses crystal formation Published online: 18 March 2014 p242 | doi:10.1038/nrneph.2014.46 PDF Glomerular disease: Albumin endocytosis is caveolin-mediated Published online: 18 March 2014 p242 | doi:10.1038/nrneph.2014.47 PDF Stem cells: The renoprotective role of miR-126 Published online: 25 March 2014 p242 | doi:10.1038/nrneph.2014.52 PDF Vascular disease: Clearing the pipes via angiophagy Published online: 25 March 2014 p243 | doi:10.1038/nrneph.2014.53 PDF IN BRIEF Dialysis: Risk of mortality increases with recovery time after dialysis | Chronic kidney disease: Ethnicity associated with early chronic kidney disease | Tubular disease: Lipotoxicity dysregulates NHE1 function, causes apoptosis | Glomerular disease: Talin1 loss in podocytes associated with nephrotic syndrome | Paediatrics: Improved survival in kidney transplant recipients | End-stage renal disease: Trends in anaemia care reveal change in practice | Chronic kidney disease: Cystic disease associated with increased risk of ESRD | Hypertension: Drug treatment more effective than renal denervation PDF
NEWS AND VIEWS		Top
Cardiovascular disease: Still unresolved: warfarin in ESRD with atrial fibrillation Wolfgang C. Winkelmayer Published online: 18 March 2014 p244 | doi:10.1038/nrneph.2014.48 Well-controlled oral anticoagulation lowers the risk of ischaemic stroke in patients with atrial fibrillation; however, conflicting evidence exists on its benefits and risks in patients with end-stage renal disease. Shah and colleagues examined this question in a large cohort of patients on dialysis who were diagnosed with atrial fibrillation. Full Text | PDF
Targeted therapies: Is there a role for rituximab in nephrotic syndrome? John Feehally Published online: 11 March 2014 p245 | doi:10.1038/nrneph.2014.37 Anti-CD20 therapy is increasingly being used in the treatment of various patterns of nephrotic syndrome in adults and children. However, its use is still based largely on observational studies and expert opinion. Well-designed randomized controlled trials are urgently needed to define the role of this expensive therapy. Full Text | PDF
Imaging: BOLD assessment—effects of RAAS inhibition in CKD Lilach O. Lerman Published online: 25 March 2014 p247 | doi:10.1038/nrneph.2014.58 Blood-oxygen-level-dependent MRI enables noninvasive assessment of renal deoxyhaemoglobin levels and, therefore, hypoxia. As decreased tissue oxygenation might contribute to acute and chronic kidney disease (CKD), this tool has been examined in patients with CKD. Indeed, the benefits of renin-angiotensin-aldosterone system inhibitors might be partly conferred by increased oxygenation. Full Text | PDF
CORRECTION		Top
The effect of RAAS blockade on the progression of diabetic nephropathy Sara S. Roscioni, Hiddo J. Lambers Heerspink & Dick de Zeeuw Published online: 11 March 2014 p243 | doi:10.1038/nrneph.2014.51 Full Text | PDF
REVIEWS		Top
MicroRNAs in IgA nephropathy Cheuk-Chun Szeto & Philip K.-T. Li Published online: 08 April 2014 p249 | doi:10.1038/nrneph.2014.50 Genome-wide analyses have identified a number of novel microRNAs (miRNAs) related to immunological and pathological changes in the kidney. In this Review, the authors describe the various purported roles of these miRNAs in IgA nephropathy, including in the aberrant glycosylation of IgA1 that has a central pathogenetic role in the early phase of this disease. Abstract | Full Text | PDF
Novel targets of antifibrotic and anti-inflammatory treatment in CKD Anne-Emilie Declèves & Kumar Sharma Published online: 25 March 2014 p257 | doi:10.1038/nrneph.2014.31 Chronic kidney disease (CKD) is becoming a worldwide epidemic, largely due to the increased prevalence of obesity and diabetes in the general population. As a consequence, new targets and treatments are urgently required to reduce the burden of CKD and the need for renal replacement therapy in affected patients. Here, the authors discuss new insights into the fibrotic and inflammatory pathways that lead to CKD and highlight novel targets for potential disease-arresting therapies. Abstract | Full Text | PDF
Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease Julia J. Scialla & Myles Wolf Published online: 01 April 2014 p268 | doi:10.1038/nrneph.2014.49 High serum levels of phosphate and fibroblast growth factor (FGF)-23 are associated with an increased risk of adverse cardiovascular events. In this Review, the authors discuss experimental and epidemiological data that supports high levels of phosphate or FGF-23 as risk factors for cardiovascular events in patients with or without chronic kidney disease. Abstract | Full Text | PDF
Renal involvement in antiphospholipid syndrome Savino Sciascia, Maria José Cuadrado, Munther Khamashta & Dario Roccatello Published online: 18 March 2014 p279 | doi:10.1038/nrneph.2014.38 Antiphospholipid syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies and thrombotic events. The kidney is a major target organ of APS, which is often present in association with other autoimmune disorders. In this Review, Sciascia et al. discuss the broadening spectrum of renal events associated with APS and the different therapeutic approaches that might be required for effective treatment. Abstract | Full Text | PDF
PERSPECTIVES		Top
SCIENCE AND SOCIETY Drug discovery in renal disease—towards a more efficient framework Toshio Miyata, Tsuyoshi Ando, Hisami Hiragi, Kanako Watanabe, Fumi Yamamoto, Douglas E. Vaughan, Tatsuo Kurokawa, Yoshiteru Oshima, Charles van Ypersele de Strihou & Masahiro Takeuchi Published online: 18 March 2014 p290 | doi:10.1038/nrneph.2014.36 The discovery and clinical development of new drugs—particularly therapies for kidney diseases—is a lengthy and costly process. Here, the authors discuss the need for closer collaboration between academia, industry and regulatory authorities to enable novel, efficient strategies for preclinical and clinical drug development. They also describe the current Japanese framework implemented to facilitate such collaboration. Abstract | Full Text | PDF
Advertisement
Download the new NatureJournals app and gain access to Nature and all Nature-branded research and review journals. All news content and open access articles are free. Subscribe to additional journals in the app for just $35.99*.  *Apple exchange rates apply. Limited time offer available on all journals except Scientific Reports. iPad, iPhone and iPod touch are trademarks of Apple Inc.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Nephrology was previously published as Nature Clinical Practice Nephrology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.